Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled PeriodAnthony A. Portale, Karl Insogna, Thomas O. Carpenter et al.|Calcified Tissue International|2019Cited by 160
Complete Steroid Avoidance Is Effective and Safe in Children With Renal Transplants: A Multicenter Randomized Trial With Three-Year Follow-UpMinnie Sarwal, Oscar Salvatierra, Elaine S. Kamil et al.|American Journal of Transplantation|2012Cited by 153
Plasma calcium oxalate supersaturation in children with primary hyperoxaluria and end-stage renal failureBernd Höppe, Craig B. Langman, Markus J. Kemper et al.|Kidney International|1999Cited by 136
Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extensionKarine Briot, Erik A. Imel, Anthony A. Portale et al.|RMD Open|2021Cited by 72
Characterization of FGF23-Dependent Egr-1 Cistrome in the Mouse Renal Proximal TubuleAnthony A. Portale, Farzana Perwad|PLoS ONE|2015Cited by 31